Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-01-19
2011-11-29
Fay, Zohreh A (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S912000
Reexamination Certificate
active
08067406
ABSTRACT:
An alkyl ether derivative represented by the following general formula [1]or its salt: wherein R1and R2represent each a substituent such as hydrogen, halogeno or alkyl; R3represents alkylamino, amino or hydroxyl; the ring A represents a 5- or 6-membered aromatic heterocycle or a benzene ring; m and n are each an integer of from 1 to 6; and p is an integer of from 1 to 3; shows an effect of protecting retinal nerve cells and, therefore, is useful as a preventive and/or a remedy for retinal nerve diseases such as glaucoma, diabetic retinopathy, retinal artery obstruction, retinal venous obstruction, macular degeneration and retinopathy of prematurity.
REFERENCES:
patent: 7087594 (2006-08-01), Saitoh et al.
patent: 7342043 (2008-03-01), Nakada et al.
patent: 2141729 (1995-08-01), None
patent: 0 873 990 (1998-10-01), None
patent: 1 325 744 (2003-07-01), None
patent: 2 521 136 (1983-08-01), None
patent: 7-304717 (1995-11-01), None
patent: 8-506807 (1996-07-01), None
patent: 8-511783 (1996-12-01), None
patent: 11-263773 (1999-09-01), None
patent: 4398247 (2009-10-01), None
patent: 95/00486 (1995-01-01), None
patent: 97/11054 (1997-03-01), None
patent: 02/30420 (2002-04-01), None
patent: 02/100833 (2002-12-01), None
patent: 03/035647 (2003-05-01), None
Mayo Clinic, Stargardt's disease: Can it be treated?, 2006, printed May 27, 2008, MayoClinic.com, http://www.mayoclinic.com/print/stargardts-disease/AN00846/METHOD=print, 2 pages.
www.AMD.org, What Is AMD?, printed from http://www.amd.org/what-is-amd.html on Aug. 3, 2010, 2 pages.
Masuzawa et al., A Model of Retinal lschemia-Reperfusion Injury in Rats by Subconjunctival Injection of Endothelin-1 , 2006,Experimental Biology and Medicine , 231:1085-1089.
Rosenbaum et al., Functional and Morphologic Comparison of Two Methods to Produce Transient Retinal lschemia in the Rat, Mar. 2001, Journal of Neuro-Ophthalmology, 21(1):62-68.
Youn et al., Effects of 400 nm, 420 nm, and 435.8 nm radiations on cultured human retinal pigment epithelial cells , 2009, Journal of Photochemistry and Photobiology B: Biology, vol. 95, Issue 1, pp. 64-70.
Anderson et al., Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration, Exp Eye Res. Feb. 2004;78(2), printed from http://www.ncbi.nlm.nih.gov/pubmed/14729357, Abstract only, 1 page.
Deutman et al., Dominantly inherited drusen of Bruch's membrane, Br J Ophthalmol. Jun. 1970.; 54(6): 373-382.
Rosenbaum, et al., Functional and Morphologic Comparison of Two Methods to Produce Transient Retinal Ischemia in the Rat, Journal of Neuro-Opthalmology, vol. 21, No. 1, pp. 62-68 (Mar. 2001).
Masuzawa, et al., A Model of Retinal Ischemia-Reperfusion Injury in Rats by Subconjunctival Injection of Endothelin-1, Experimental Biology and Medicine, vol. 231, pp. 1085-1089 (2006).
http//www.wrongdiagnosis.com, Prognosis of Age-related macular degeneration, http.//www.wrongdiagnosis.com/a/age—related—macular—degeneration/prognosis.htm 3 pages (printed May 7, 2009).
Pang, et al., Acute effects of glaucoma medications on rat intraocular pressure, Experimental Eye Research, vol. 80, No. 2, pp. 207-214 (Feb. 2005).
Mayo Clinic staff, Diabetic retinopathy-Treatments and drugs, www.mayoclinic.com, printed from http://www.mayoclinic.com/health/diabetic-retinopathy/DS00447/DSECTION=treatments%2Dand%2Ddrugs, 4 pages (2008) (printed on May 7, 2009).
The Foundation Fighting Blindness, Animal Models for Studying, Inherited Degenerative Retinal Disease, The Foundation Fighting Blindness, printed from www.retina-international.org/sci-news/animmod.doc , 23 pages (2000) (printed on Jan. 11, 2009).
Mayo Clinic Stargardt's disease: Can it be treated?, http://www.mayoclinic.com/print/stargardts-desease/AN00846/METHOD=print, 2 pages (2006).
National Eye Institute, Retinopathy of Prematurity (ROP), http://www.nei.nih.gov/helath/rop/, 6 pages (2008)(printed on May 7, 2009).
Zhang, et al., Activation of the Mitochondrial Apoptotic Pathyway in a Rat Model of Central Retinal Artery Occlusion, Investigative Opthalmology and Visual Science, vol. 46, pp. 2133-2139 (2005).
Newman, Hereditary Optic Neuropathies: From the Mitochondria to the Optic Nerve, American Journal of Opthalmology, vol. 140, pp. 517-523 (Sep. 2005).
Schmidt-Erfurth, et al., Management of neovascular age-related macular degeneration, Progress in Retinal and Eye Research, vol. 26, pp. 437-451 (2007).
Merck Manual Online Medical Library, Age-Related Macular Degeneration, Merck Manual-printed from http://www.merck.com/mmpe/print/sec09/ch106/ch106b.html, 2 pages (2005) (printed on Oct. 20, 2008).
Moalem, et al., Differential T cell response in central and peripheral nerve injury: connection with immune privilege, The FASEB Journal, vol. 13, pp. 1207-1217 (1999).
Stedman's Medical Dictionary 27thEdition, remedy, printed from http://www.thomsonhc.com/pdrel/librarian/PFDefaultActionld/pdrcommon.Stedmans, 1 page (2000) (printed on Oct. 20, 2008).
Merck Manual Online Medical Library, Diabetic Retinopathy, Merck Manual-printed from http://www.merck.com/mmpe/print/sec09/ch106/ch106e.html, 2 pages (2005) (printed on Oct. 20, 2008).
Hyojun Ganka Gaku, 7thEdition, pp. 103-107, Igaku-Shoin Ltd. (1998).
Haruki, Abe: Atarashii Ganka, vol. 19, No. 7, pp. 903-912 (2002) (with English abstract).
“Agouron buys drug discovery company” “Chiroscience slaps up licensing talks”, SCRIP, No. 2229, p. 13 (May 6/9, 1997).
“Allergan's1997 sales fall”, SCRIP, No. 2307, p. 10 (Feb. 8, 1998).
MedlinePlus, Retinal artery occlusion, Apr. 22, 2008, U.S. National Library of Medicine and National Institutes of Health, printed from http://www.nlm.nih.gov/medlineplus/ency/article/001028.htm on Apr. 7, 2010,3 pages.
MayoClinic.com, Dry macular degeneration, Aug. 26, 2008, MayoClinic.com, printed from http.//www.mayoclinic.com/health/macular-dengeneration/DS00284/METHOD=print&DSECTION=all on Apr. 7, 2010, 13 pages.
Merck Manuals, Hereditary Optic Neuropathies, 2005, http://www.merck.com/mmpe/print/sec09/ch107/ch107b.html printed May 27, 2008, 2 pages.
Merck Manuals, Retinitis Pigmentosa, 2005, http.//www.merck.com/mmpe/print/sec09/ch106/ch106h.html printed May 27, 2008, 2 pages.
Youn, et al, Effects of 400 nm, 420 nm, and 435.8 nm radiations on cultured human retinal pigment epithelial cells, Journal of Photochemistry and Photobiology B: Biology, vol. 95, Issue 1, pp. 64-70 (2009).
U.S. Appl. No. 12/985,616, filed Jan. 6, 2011, Saitoh, et al.
Iwakami Noboru
Kimura Tatsuo
Saitoh Akihito
Fay Zohreh A
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Toyama Chemical Co., Ltd.
LandOfFree
Preventive/remedy for retinal nerve diseases containing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventive/remedy for retinal nerve diseases containing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventive/remedy for retinal nerve diseases containing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278813